Answers are grounded in this paper and cite their sources.
BACKGROUND: Early-life epigenetic mechanisms may contribute to the developmental programming of childhood obesity. We aimed to examine whether placental asparaginase (ASPG) DNA methylation (DNAm) is associated with adiposity at 6 years of age and to explore its cross-tissue patterns and parent-child concordance. METHODS: In a prospective birth cohort, placental ASPG DNAm was quantified by pyrosequencing and related to anthropometric and cardiometabolic outcomes in children at 6 years (n = 180). DNAm was also measured in child peripheral blood (n = 127) and in maternal and paternal blood samples during pregnancy (n = 44). RESULTS: Increased placental ASPG DNAm was associated with increased adiposity and cardiometabolic markers at 6 years and increased odds of overweight/obesity [odds ratio (OR) = 1.06, 95% confidence interval (CI) = 1.01-1.11, P = 0.01]. Similar associations were observed for child blood (OR = 1.19, 95% CI = 1.04-1.36, P = 0.01), although these analyses were cross-sectional. Placental and child DNAm levels were positively correlated (r = 0.40, P < 0.01), and maternal-child DNAm was concordant (r = 0.48, P < 0.01), although the parental analyses were exploratory and based on a limited sample size (n = 44). CONCLUSIONS: ASPG DNAm is associated with childhood adiposity and shows cross-tissue and parent-child concordance, suggesting its potential role as an early-life epigenetic marker associated with metabolic risk. Given the modest effect sizes and exploratory nature of some analyses, these findings warrant cautious interpretation and require replication in independent cohorts.
No takes yet. Share an insight, caveat, or question.
Niubó-Pallàs et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: